Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
135,488,140
-
Total 13F shares
-
95,670,815
-
Share change
-
-4,753,771
-
Total reported value
-
$1,853,291,674
-
Put/Call ratio
-
278%
-
Price per share
-
$19.37
-
Number of holders
-
269
-
Value change
-
-$144,256,200
-
Number of buys
-
115
-
Number of sells
-
125
Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) as of Q3 2024
As of 30 Sep 2024,
ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) was held by
269 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
95,670,815 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, Avoro Capital Advisors LLC, STATE STREET CORP, FMR LLC, Slate Path Capital LP, T. Rowe Price Investment Management, Inc., GEODE CAPITAL MANAGEMENT, LLC, Siren, L.L.C., and UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC.
This page lists
267
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.